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ABSTRACT 
 
The role of adrenal androgens as drivers for castration-resistant prostate cancer (CRPC) growth in 
man is generally accepted; however,  the value of preclinical mouse models of CRPC is debatable, 
since mouse adrenals do not produce steroids activating the androgen receptor. In this study, we 
confirmed the expression of enzymes essential for de novo synthesis of androgens in mouse 
adrenals, with high intratissue concentration of progesterone (P4), and moderate levels of 
androgens, such as androstenedione, testosterone, and dihydrotestosterone in the adrenal glands of 
both intact and orchectomized (ORX) mice. ORX alone had no effect on serum P4 concentration, 
whereas orchectomized and adrenalectomized (ORX+ADX) resulted into a significant decrease in 
serum P4, and into a further reduction in the low levels of serum androgens (androstenedione, 
testosterone, and dihydrotestosterone), measured by mass spectrometry. In line with this, the serum 
PSA and growth of VCaP xenografts in mice after ORX+ADX was markedly reduced compared to 
ORX alone, and the growth difference was not abolished by a glucocorticoid treatment. Moreover, 
ORX+ADX altered the androgen-dependent gene expression in the tumors similar to that recently 
shown for the enzalutamide treatment. These data indicate that that in contrast to the current view, 
and similar to human, mouse adrenals synthesize significant amounts of steroids that contribute to 
the androgen receptor–dependent growth of CRPC.  
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INTRODUCTION 
 
Prostate cancer (PCa) is the second most common cancer and fifth leading cause of death from 
cancer in men worldwide1. At early stages of PCa, when the cancer is clinically localized, the 
disease is curable with surgery or radiation, whereas systemic therapies are needed for the 
management of advanced disease. Androgens, acting via the androgen receptor (AR) are essential 
for PCa growth 2. Accordingly, androgen deprivation therapy (ADT), achieved by suppression of 
gonadal androgen synthesis via orchectomy (ORX) or chemically with gonadotropin-releasing 
hormone (GnRH) analogs, has been the first-line treatment of advanced and metastatic prostate 
cancer over 70 years. Although the initial response to these treatments is nearly complete, the 
majority of patients become resistant to ADT, developing a lethal castration-resistant prostate 
cancer (CRPC) 3. In most cases, the CRPC growth involves reactivation of the AR signaling. This 
concept has been clinically proven with two recently approved treatments for CRPC. These include 
a non-steroidal AR antagonist (enzalutamide) that also inhibit the nuclear translocation of AR 4, and 
a selective CYP17A1 inhibitor (abiraterone acetate) blocking the critical step in androgen 
biosynthesis 5–7. Also several other new treatments targeting directly the AR signaling pathway are 
under development 8,9. Despite improved response ratios and overall survival with the new 
treatments, current therapies are not curative 8,10. 
 
It is known that therapies leading to suppression of androgen action may lead to the development of 
AR pathway–related resistance mechanisms, including AR gene amplification 11 or overexpression 
12
, production of mutated forms of AR 13,14 or AR splice variants 15,16, and the induction of 
intratumoral androgen biosynthesis 17,18.  Approximately 90% to 95% of circulating androgens in 
men are expected to be produced in testis and the remaining 5% to 10% in the adrenal cortex 19. 
Under ADT, normal and cancerous prostate tissue have shown to utilize adrenal-derived DHEA for 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
   
 
4 
 
the local synthesis of T and dihydrotestosterone (DHT) 20,21. However, the significance of adrenal 
androgens in the development of CRPC has been difficult to establish. Results have also shown  
that certain PCa cell lines (PC346 and VCaP) predominantly exploit adrenal precursors for 
androgen production, whereas others (LNCaP) utilize equally well both adrenal precursors and de 
novo synthesis 17,21,22. On the other hand, in clinical CRPC specimens, only low intratumoral levels 
of enzymes of the first steps of steroid synthesis have been observed, but an up-regulation of 
enzymes essential for conversion of adrenal precursors to active androgens were reported, 
suggesting a central role for the adrenal precursors in androgen production 20,23. Furthermore, the 
mutated AR (T878A) expressed, eg. in LNCaP cells, is also activated by the precursors of androgen 
production, including progesterone 24,25. 
 
In contrast to human, murine adrenals do not produce large quantities of DHEA or its sulphate 
(DHEA-S), partially due to the low levels of CYP17A1 26, and thus, the value of preclinical mouse 
models for studying androgen-dependency of CRPC has been questioned. In the present study, 
VCaP xenografts were used to study the role of murine adrenal steroids in CRPC growth. VCaP 
cells, originally established from a vertebral bone metastasis of a patient with CRPC 27, express 
wild type AR 27, and the VCaP xenografts in ORX mice demonstrate key characteristics of clinical 
CRPC, including up-regulation of intratumoral androgen biosynthesis, aberrant expression of both 
full-length AR and various AR splice variants, and responsiveness to AR antagonists 28,29. The 
results show that ADX attenuates VCaP tumor growth in ORX mice, and results in reduction of 
intratumoral DHT, as well as down-regulation of androgen-dependent genes. Our data indicate that 
the steroid synthesis machinery in the mouse adrenal cortex contributes to the androgen-dependent 
growth of VCaP xenografts in castrated mice. 
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MATERIALS AND METHODS 
 
Cell lines 
VCaP cells were obtained in 2006 from the American Type Cell Culture (ATCC, Manassas, VA) 
and were tested and authenticated by short-tandem repeat analysis in January 2014. All cell culture 
reagents were purchased from Gibco, Life Technologies (Carlsbad, Canada), except fetal bovine 
serum which was obtained from Hyclone Laboratories Inc. (Logan, UT). 
 
Generation of VCaP xenografts  
Athymic Nude male mice (Hsd:Athymic Nude-Foxn1nu, Envigo, Gannat, France) at approximately 
five to six weeks of age, weighing between 20 to 30 g, were used in the studies. The mice were 
housed in individually ventilated cages under controlled conditions of light (12 h light /12 h dark), 
temperature (22 ±2 ºC) and humidity (55% ±15%) in specific pathogen-free conditions at the 
animal facilities of Orion Corporation, Orion Pharma, Finland. The mice were given irradiated soy-
free natural-ingredient feed [RM3 (E), Special Diets Services, UK] and filtered, UV treated, tap 
water ad libitum. To maintain sodium balance, ORX+ADX mice had unlimited access to 0.9 % 
sodium chloride (Baxter, Deerfield, IL), instead of water. 
 
Four to six days before inoculation, the cells were divided to confirm optimal growth potential in 
mice. At the day of inoculation, the cells growing at 80 % confluence were harvested using 0.05 % 
Trypsin-EDTA, centrifuged, counted, and suspended in the culture medium described above at a 
density of 26.6 x106 cells/mL. High protein concentration Matrigel™ (BD Biosciences, Bedford, 
MA) was then added (1:1), and a 150 µL aliquot of this suspension (2 million cells/mice) were 
inoculated s.c. to the right flank of each mouse by using a 25 G needle. 
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VCaP xenograft growth in intact, orchectomized, and both orchectomized and 
adrenalectomized mice 
Development and growth of the VCaP tumors was monitored by measuring the tumor volume twice 
a week, and by detecting the serum concentration of prostate specific antigen (PSA) every 10 days. 
The volume of the tumors was calculated according to following formula:  
 
W2 * L / 2 (W = shorter diameter, L = longer diameter of the tumor). 
 
For PSA analysis, blood was collected from saphenous vein, and the PSA was measured with a 
time-resolved fluorometer (Wallac, PerkinElmer Analytical Life Sciences, Turku, Finland) as 
described previously 30. Kim Pettersson (University of Turku, Finland) kindly provided reagents for 
the PSA assay. 
 
Tumors were grown for seven weeks, until the mean volume of the tumors reached approximately 
300 mm3 (range 51 to 691 mm3), and the mean serum PSA value was approximately 20 µg/L (range 
1 to 93 µg/L). The experimental groups: intact (n=15), orchectomized (ORX; n=14), and both 
orchectomized and adrenalectomized (ORX+ADX; n=14) mice were allocated to study groups 
using our recently published algorithm 31, which matches the animals based on their baseline PSA 
concentration, tumor volume, PSA change from previous week, and animal weight to guarantee 
balanced and randomized allocation process. Following the ORX and ADX, the tumor volumes and 
the serum PSA were measured for eight subsequent weeks. At the end of the experiment the mice 
were sacrificed, and serum, adrenal glands, and tumors were collected for further analyses. Samples 
for steroid measurements and RNA isolation were stored at -80 oC after initial freezing in liquid 
nitrogen 29. 
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VCaP xenograft growth in both orchectomized and adrenalectomized mice with 
corticosterone treatment 
The VCaP tumors were initially established as described above in intact mice. When the tumors 
reached approximately 300 mm3 (range 46-610 mm3) the mice were allocated into three groups: 
ORX (n=13), ORX+ADX (n=13), and ORX+ADX with corticosterone treatment (n=13). ORX and 
ADX interventions were performed as described above, and after operations, corticosterone (Sigma-
Aldrich, St.Louis, MO) was provided orally for four weeks (3 mg/kg/day) until the end of the study. 
The dose of corticosterone was selected based on literature 32 and on our previous studies. The 
appropriate range of used dose was also verified by measuring of plasma ACTH levels at the time 
of necropsy, ie, 24 h after last dose of corticosterone (Milliplex MAP Rat Pituitary Magnetic Bead 
Panel, Millipore Corporation, Billerica, MA). At the end of the study, adrenal glands and tumors 
were dissected and snap-frozen, blood samples were collected by cardiac puncture, and serum was 
separated and stored in -80 ºC. 
 
National  Animal Experiment Board of Finland have authorized the animal experiments with the 
licenses ESAVI/7472/04.10.03/2012 and ESAVI/1993/04.10.03/2011, and studies are performed 
according to the instructions given by Institutional Animal Care and Use Committees of University 
of Turku and Orion Pharma. The  animals  were  kept  according  to  the  Guide  for  the  Care  and  
Use  of  Laboratory Animals published by the National Institute of Health (NIH). 
 
Measurement of intratumoral and serum steroids 
Tumors were homogenized in sterile water using a TissueLyzer LT homogenizer (Qiagen, Venlo, 
The Netherlands), and intratumoral, intra-adrenal, and serum concentrations of P4, A-dione, T, and 
DHT were measured using a previously described method applying GC-MS/MS 33. Using mouse 
serum, the lower limit of quantitation (LLOQ) for P4, A-dione, T, and DHT with the assay are 74 
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pg/mL, 12 pg/mL, 8 pg/mL, 2.5 pg/mL, respectively. Results under the LLOQ were calculated to be 
half of each LLOQ value to avoid overestimation of low values in the analysis. To make 
intratumoral steroid concentrations comparable to those in the serum, 1 g of tumor was considered 
equivalent to 1 mL of serum.  
 
Quantitative RT-qPCR analyses and RNA-seq analyses 
Total RNA for RT-qPCR and RNA-seq were extracted from tumor and adrenal gland samples using 
TRIsure (Invitrogen, Carlsbad, CA), and purified using RNeasy Mini Kit (Qiagen) according to 
manufacturer’s instructions. The primers and conditions for RT-qPCR analysis are shown in Table 
1. The RNA-sequencing (RNA-seq) analyses of intact (n=5) and ORX (n=6) adrenal glands were 
performed at the Finnish Functional Genomics Centre, University of Turku and Åbo Akademi 
University and Biocenter Finland. The amount of 300 ng of total RNA was used according to 
Illumina TruSeq® Stranded mRNA Sample Preparation Guide. The samples were sequenced with 
Illumina HiSeq 2500 instrument (Illumina, San Diego, CA) using Hiseq v2 Rapid sequencing 
chemistry and 50 bp single-end read length. 
 
The quality of the sequenced reads was checked using FastQC tool. STAR v2.5.0c 34 was used to 
align the reads to the mouse reference genome mm10, available at UCSC (Illumina iGenomes web 
site, San Diego, CA). The number of uniquely mapped reads associated with each gene according to 
RefSeq gene annotation was counted using the subread v1.5.0 R-package 35. The RNA-seq data are 
available from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/; 
accession number GSE117771). The downstream analysis of the data was performed using R 
version 3.2.2 36 and its corresponding Bioconductor module 3.2 37. The count data were normalized 
for library size using the Trimmed Mean of M-values (TMM) method implemented in the edgeR R-
package 38. The normalized data were further transformed using the voom approach in the limma R-
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package 39. R package ROTS 40 was used for performing the statistical testing and false discovery 
rate (FDR) < 0.05 and absolute fold change > 2 was required for detecting the differentially 
expressed genes between the intact and ORX groups. The hierarchical clustering of the scaled 
normalized expression values of differentially expressed AR-regulated genes was performed using 
Euclidean distance and Ward’s method, implemented in the R package pheatmap 41.  
 
Immunoblotting 
Tumor and adrenal gland samples were homogenized using a TissueLyzer LT and stainless steel 
beads (Qiagen, Hilden, Germany) in RIPA-lysis buffer containing the following: 150 mmol/l Tris-
HCl, 1 % NP-40, 0.5 % sodium deoxycholate, 1 mmol/L EDTA, 1 mmol/L SDS, 100 mmol/L 
sodium orthovanadate (Sigma-Aldrich, St.Louis, MO), and cOmplete Mini protease inhibitor 
(Roche Diagnostics, Mannheim, Germany). AR was immunoblotted with standard techniques, as 
previously shown 28. ImageJ software version 1.51K (NIH, Bethesda, MD) was used to compare 
and quantify the intensity of bands on scanned images of membranes. 
 
Statistical analysis 
The statistical tests were chosen depending on the results of the preliminary Shapiro-Wilk tests of 
data normality. Non-parametric Mann-Whitney, Kruskal-Wallis, and Dunn’s multiple comparison 
tests were applied in RT-qPCR comparisons on single gene level, and to test the differences in the 
steroid concentrations in intact, ORX, and ORX+ADX mice, in comparison to vehicle and 
corticosterone-treated animals. Correlation of Cyp17a1 and Lhcgr mRNA expression in adrenal 
gland was calculated using Spearman correlation coefficient. These univariate statistical analyses 
were performed using GraphPad Prism 7 software (GraphPad Software, San Diego, CA). The 
longitudinal analysis of PSA profiles between the interventions was performed using mixed-effects 
models that infer differences in population growth slope co-efficients over the whole time period of 
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the intervention 42, where the individual prognostic baseline variables were accounted for by 
incorporating them in the baseline animal matching 31. The R statistical software (version 3.2.1) 36 
together with the preclinical analysis R-package hamlet (version 0.9.5) were utilized in the 
longitudinal analyses 31. P-value < 0.05 was considered statistically significant. 
 
RESULTS 
 
Growth of castration-resistant VCaP tumors is partially adrenal driven 
Orthotopic VCaP xenografts in ORX hosts display the fundamental properties of CRPC, namely 
androgen-dependent growth and secretion of PSA, as well as AR overexpression and up-regulation 
of full-length AR and its splice variants 28. In the present study, similar growth properties were 
confirmed for subcutaneous VCaP xenografts. As expected, ORX and ORX+ADX caused a 
transient repression of tumor growth rate and serum PSA concentrations (Fig. 1A, B). Notably, 
ADX delayed the relapse and reduced tumor growth in ORX mice. At the end of the study the 
tumor volumes in the ORX+ADX mice were smaller (P < 0.001) than those in the ORX group 
(Fig.1A). Similar pattern was observed in serum PSA concentrations (Fig. 1A). One week post 
ORX, PSA concentration reduced 6-fold, (from 20 µg/L to 3.4 µg/L), whereas 22-fold decline 
(from 20 µg/L to 0.9 µg/L) was seen in ORX+ADX mice. In the ORX group, serum PSA reached 
the pre-castration levels at about seven weeks, but in ORX+ADX group the increase in PSA levels 
was less evident and did not reach the pre-castration levels within the nine week–long study period 
(Fig. 1B). At the end of the study, PSA concentration in ORX+ADX mice was significantly (P < 
0.05) lower compared to ORX mice Thus, these data show that ADX significantly reduces the 
growth of the castration-resistant VCaP tumors, indicating a contribution of adrenals to the CRPC 
xenograft growth in mice. 
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The possible role of glucocorticoids in ADX response was next studied. Corticosterone replacement 
at physiological dose had no effect on the growth of VCaP xenografts in ORX+ADX mice (Fig. 
1C). ORX, however, significantly (P < 0.01) increased the weights of adrenals (Fig. 1D), and as 
expected, ORX+ADX resulted into a marked increase in serum ACTH-level (26-fold higher 
compared to ORX), whereas a smaller change (7-fold compared to ORX, Fig. 1E) was observed in 
corticosterone-treated mice. These data confirm that the inhibition of VCaP xenograft growth by 
ADX is not due to the lack of adrenal glucocorticoids. 
 
Mouse adrenals express enzymes involved in androgen production  
Since the lack of glucocorticoids did not explain the inhibition of VCaP xenograft growth in 
ORX+ADX group, the expression of adrenal enzymes involved in sex steroid biosynthesis was 
analyzed by RNA-seq and RT-qPCR analysis (Fig. 2A, B, and D). Interestingly, RNA-seq revealed 
mRNA expression of 59 CYP, 16 AKR, and 62 SDR family enzymes. These include both classical 
steroid biosynthesizing enzymes, as well as several other enzymes whose role in steroid synthesis is 
yet to be defined, suggesting various possible pathways for androgen production. Some of these 
enzymes are known to be involved in early stages of steroid synthesis and, thus, affect both 
glucocorticoid and androgen production, whereas some are more specifically related to androgen 
production. Of these, the mRNA expression of Akr1c6 (homolog for human AKR1C4), Akr1c18, 
Akr1d1, Cyp17a1, Ugt1a1, Cyp11a1, Hsd3b1, Hsd3b2, Srd5a1, and Srd5a3 were confirmed by RT-
qPCR and were shown to be induced 1.6 to 3736.6-fold by ORX (P < 0.01 to 0.001), with highest 
induction in the expression of Akr1c18 (Fig. 2A, B). Furthermore, ORX resulted in marked up-
regulation of luteinizing hormone/choriogonadotropin receptor (Lhcgr, 29-fold, P < 0.005), and 
significant up-regulation of the melanocortin 2 receptor (also known as adrenocorticotropic 
hormone receptor, Mc2r, 2-fold, P < 0.001) and Ar expression (2-fold, P < 0.001) in the adrenals 
(Fig. 2C). Interestingly, a close correlation between the Cyp17a1 and Lhcgr mRNA expression was 
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observed (P < 0.001, Fig. 2E), suggesting that high circulating luteinizing hormone (LH) induces 
the early steps of the adrenal steroidogenesis in ORX mice. Top 30 up-regulated and down-
regulated genes in the RNA-seq data in mouse adrenal gland are shown in Supplementary Table S1. 
 
Mouse adrenals produce active androgens and their precursors, and contribute to sex steroid 
production in VCaP xenografts in castrated mice  
The enzymatic machinery in adrenal glands, possibly involved in the androgen biosynthesis, 
prompted us to analyze the intra-adrenal steroid concentrations of intact and ORX male mice. Our 
data showed that, together with P4, high concentrations (>1 ng/g tissue) of all main classical 
androgens (A-dione, T, and DHT) were present in the adrenals of intact mice. The mean 
concentrations of P4, A-dione, T, and DHT were 4,367, 1.7, 3.0, and 1.5 ng/g, respectively (Fig. 
3A). Thus, the P4 concentration was over 1,000-fold higher than any of the quantitated androgens. 
In addition, high tissue-serum ratios for A-dione (84:1), DHT (94:1), and P4 (50000:1) indicate 
local synthesis of these steroids in the adrenal glands (Fig. 3B). Interestingly, ORX had no effect on 
intra-adrenal A-dione, T, DHT, or P4 concentrations. However, the adrenal-serum ratio of all these 
steroids increased significantly after ORX (Fig. 3B). These findings further support the hypothesis 
of intra-adrenal production of androgens in mice. 
 
Notably, ORX alone had no effect on serum or intratumoral P4 concentrations (Fig. 4A, B), whereas 
ORX+ADX resulted into 13-fold and 21-fold reduction in the P4 concentration in the serum (Fig. 
4A) and in the tumor (Fig. 4B) , respectively. This observation confirms that both serum and 
intratumoral P4 mainly originates from the adrenals. ADX further reduced T and DHT 
concentrations in the serum of ORX mice (Fig. 4A), suggesting that murine adrenals indeed 
contribute to circulating androgen concentrations. 
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In line with our previous data 28, intratumoral P4 and the androgen concentrations remained high in 
the castration-resistant VCaP tumors, despite the low serum steroid concentrations in ORX mice 
(Fig. 4B). Importantly, ADX decreased intratumoral A-dione, T, DHT, and P4 concentrations in 
ORX mice (Fig. 4B). However, intratumoral synthesis of DHT is maintained after ADX, as tumor-
serum ratio of DHT remains high. Taken together, the present data show the role of adrenals in the 
regulation of intratumoral androgen concentration in the VCaP xenografts in ORX mice. 
 
Adrenalectomy affects androgen-dependent gene expression in the CRPC VCaP tumors 
In line with our published data 28, the present study confirmed the up-regulation of mRNAs for full-
length AR and AR splice variants by ORX (Fig. 5A). Interestingly, ADX further contributed to the 
over expression of AR in castration-resistant VCaP xenografts (Fig. 5A). At the protein level, 
however, no induction by ADX was observed (Fig. 5B), likely due to lower stability of the protein 
in the presence of only a low amount of the ligand 43,44. ADX+ORX also induced the expression of 
certain enzymes involved in DHT synthesis in the tumors, including AKR1C3 and SDR5A1 (Fig. 
5C). In addition, the expression of set of genes previously 29 identified to be regulated by 
antiandrogens in castration-resistant VCaP xenografts was analyzed. Of these genes, SYLT2 and 
NOV were up-regulated and FKBP5 and ST6GAlNAcl down-regulated after ADX+ORX (Fig. 5D). 
Overall, the effect of ADX in castration-resistant VCaP xenografts was similar to that shown for 
antiandrogens (enzalutamide and apalutamide) 29 
 
 
DISCUSSION 
 
Xenograft models generated using PCa cells and clinical tissue specimens are widely used 45–47 for 
studying PCa biology and drug responses. The relevance of mouse CRPC models has, however, 
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been questioned due to species differences in extragonadal sex steroid production 17,48. In humans, 
weak androgens DHEA and DHEA-S, produced by adrenal glands, are recognized as precursors for 
the intratumoral synthesis of T and DHT 49. In contrast, production of DHEA and DHEA-S by 
murine adrenals has been considered negligible, and, thus, having no significant contribution to 
local androgen biosynthesis in CRPC xenografts 26. In the present study, this view was challenged 
by using up-to-date steroid profiling methodology, and evidence was provided for the significance 
of murine adrenal steroids in the regulation of CRPC xenograft growth. 
 
VCaP xenografts in ORX mice exhibit several of the key characteristics of clinical CRPC, including 
castration-resistant growth, intratumoral androgen biosynthesis, marked expression of both full-
length AR and various AR splice variants, and responsiveness to AR antagonists 28,29. The role of 
adrenal steroids has not been addressed in the previous VCaP xenograft studies, possibly due to the 
presumption that murine adrenals lack the enzymatic machinery needed for the production of 
androgens. Our present results, however, show that ADX attenuates VCaP tumor growth and serum 
PSA in ORX mice, indicating that adrenal steroids contribute to the growth of castration-resistant 
VCaP xenografts. In line with that previously shown for VCaP cells after enzalutamide treatment in 
vitro 50, our RNAseq data indicated the induction of glucocorticoid receptor (GR) after ADX. 
Importantly, even if data have suggested that corticosteroids might promote the growth of 
antiandrogen-resistant prostate tumors 50, the tumor inhibitory effect of ADX on VCaP xenografts 
in vivo was not abolished by a treatment with the physiological dose of corticosterone. Thus, the 
effect of ADX on VCaP xenograft growth is not explained by the lack of glucocorticoids or reduced 
general well-being of the host. Furthermore, due to their low binding affinity, the amount of 
androgens present in the tumors likely do not activate the low level of GR present in the tumors. 
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The present study demonstrates that mouse adrenals produce biologically significant amounts of T 
and DHT, and contribute to the circulating levels of these androgens, especially after ORX. RT-
qPCR analyses were in line with the steroid measurements, showing that murine adrenals express 
some of the key enzymes that selectively contribute to androgen synthesis (Hsd17b3, Akr1c6, and 
Hsd17b6) 48. The discrepancy between previous studies 26 and our current results regarding murine 
adrenal androgen production may, at least partly, be explained by methodological issues. A highly 
sensitive mass spectrometry–based method was used to measure the intratissue and serum steroid 
concentrations 33, as against the less sensitive assays used in the previous studies. In line with earlier 
data 48, it was also observed that ORX caused a marked induction in the expression of adrenal LH 
receptor (Lhcgr) expression. Interestingly, a strong correlation was observed between the 
expression of Lhcgr and Cyp17a1, encoding for a key enzyme necessary for the synthesis of all 
steroid hormones in the adrenal cortex. As ORX increases circulating LH levels 51, these data 
suggest an auto-regulatory loop for LH to promote the early steps of steroidogenesis in the murine 
adrenals. Also in human, bilateral ORX increase serum LH levels 52. Moreover, it has been shown 
that human adrenal gland express LH receptor in the adrenal cortex cells in the reticular layer 53, it 
was speculated that GnRH analog treatment may reduce adrenal steroidogenesis via suppressing the 
circulating LH. Currently, ADT is mainly achieved by chemical castration by GnRH analogs. 
However, cumulating evidence suggests that long term chemical castration is associated, for 
example, with higher risk of bone fractures and cardiovascular events compared to ORX 54. Thus, 
there has been discussion on whether surgical castration should be favored over the GnRH analog 
treatment 54–56. These data suggesting that high LH level after ORX is activating adrenal 
steroidogenesis would, however, favor the use of GnRH analogs in the treatment of PCa patients. 
 
The correlation between intratumoral and circulating androgen concentrations indicates a systemic 
contribution to intratumoral androgen levels. In addition, in ORX mice, circulating P4 is also a 
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likely precursor for the local androgen production in castration-resistant VCaP tumors. Previous 
studies have reported P4 in the circulation in mice after ORX 17,33 but its origin has not been well 
established. Some studies suggest that production of P4 in the tumors is the main source of the 
circulating P4 in PCa xenograft bearing ORX mice 22,57, whereas the current data indicate a major 
role for adrenal P4 production. It is well established that the human AR with the T878A mutation is 
strongly stimulated by P4 24, and there is some evidence to suggest that P4 may induce AR action 
under the conditions of high AR expression 2,58. As increased levels of AR are present in CRPC 
tumors 59, it is possible that also non-classical, low affinity ligands, such as P4, can stimulate AR. 
Nevertheless, P4 is only a very weak agonist for the wild-type AR (AR-FL), and based on the 
present data, i can be concluded that DHT, present at substantial concentrations in castration-
resistant VCaP xenografts, is the main driver of intratumoral AR signaling in the ORX and 
ORX+ADX mice. Notably, P4 may serve as a substrate for steroid 5α-reductases (SRD5A) in the 
backdoor pathway of DHT synthesis that bypasses the need of T as an intermediate 60. VCaP 
xenografts grown in ORX+ADX mice express SRD5A enzymes, and the intratumoral P4 and DHT 
levels are comparable to those in tumors from intact animals. This observation, together with a 
significant decrease of intratumoral T after ORX, and a further reduction after ADX, support the 
hypothesis of adrenal P4 as a precursor for intratumoral DHT synthesis via the backdoor pathway. 
Furthermore, the possible contribution of novel androgens, such as the 11-keto-T and 11-keto-DHT 
61
, to the growth of VCaP xenografts in ORX+ADX hosts remains to be determined. 
 
In line with clinical data 62, our previous study confirmed that ORX induces the expression of full-
length AR and its splice variants 28 in VCaP xenografts, and that antiandrogen treatment further 
stimulates AR expression in castration-resistant VCaP tumors 29. The present study shows that the 
effect of ADX, mimics the effect of antiandrogens, as regards the up-regulation of AR expression 
and stimulation of intratumoral DHT synthesis 29. This result suggests that attenuation of tumor 
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growth by ADX is a result of inhibition of androgen action. Moreover, ADX and enzalutamide 29 
modify the expression of androgen-dependent genes (NOV, FKBP5, and ST6GAlNAc1) in a similar 
manner, which further supports the idea of the anti-androgenic effect of ADX on the growth of 
VCaP tumors in ORX hosts. 
 
Taken together, in contrast to the current view, we have demonstrated that adrenals of intact and 
ORX mice synthesize biologically relevant levels of active androgens, as well as precursors of 
androgen synthesis, such as P4. As a result, murine adrenals significantly contribute to the growth of 
VCaP xenografts in ORX mice. Thus, mice resemble men more closely than previously thought, in 
terms of the relevance of adrenals in producing androgens and their precursors to be further 
synthesized in peripheral tissues and tumors. In conclusion, VCaP xenograft model resembles the 
clinical CRPC 63, and is an appropriate model to study androgen-dependent growth of CRPC and 
the mechanisms involved therein. Furthermore, the complete blockade of adrenal steroid synthesis, 
including all potential precursors for DHT, may be an additional option for prostate cancer patient. 
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FIGURE LEGENDS 
 
Fig. 1. Combined orchectomy (ORX) and adrenalectomy (ADX) attenuates VCaP tumor growth 
more efficiently than ORX alone, measured by serum PSA concentration (A) and tumor volume 
(B). C: Glucocorticoid (corticosterone) treatment does not abolish the effect of ADX on tumor 
growth in ORX mice. D: The relative weight of adrenal glands of ORX mice is increased compared 
to intact mice. The mean weight was 0.41 g (median 0.39 g, range 0.20 to 0.86 g) in ORX group, 
and 0.30 g (median 0.28 g, range 0.18 to 0.60 g) in intact group. Measurements were performed at 
the end of the study, 63 days after ORX or with intact 84 days after cell inoculations. E: Serum 
ACTH concentration in ORX+ADX group is partially normalized by corticosterone treatment. 
Measurements were performed at the end of the study, 30 days after ORX and ORX+ADX. The 
data shown in A, B, and C represent mean±SEM and data in D and E represent median and range. 
The statistical tests utilized were the following: Longitudinal mixed-effects models, as presented in 
31
, were applied for data presented in A and B. Kruskal-Wallis with Dunn’s post hoc test at sacrifice 
was used for the data in C. Mann-Whitney U test was applied for the data in D and E. *P < 0.05, 
**P < 0.01, ***P < 0.001. 
 
Fig. 2. A: Relative mRNA expression of the top five most up-regulated enzymes (A) and other 
enzymes (B) related to steroid synthesis in adrenal gland of intact (n= 11, white bars) and 
orchectomized (ORX; n=11, gray bars) male mice. C: Expression of LH receptor (Lhcgr), the 
receptor for ACTH (Mc2r), and androgen receptor (Ar) in intact and ORX mice. D: Heat map of 
hierarchical clustering of the differently expressed enzymes in intact (n= 4) and ORX (n=5) mice 
adrenal gland. E: Spearman correlation between the expression of Cyp17a1 and Lhcgr. All 
measurements were performed at the end of the study, 63 days after ORX or with intact 84 days 
after cell inoculation. Data in A and C are expressed as mean±SEM. RT-qPCR results are 
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normalized to L19 expression. Mann-Whitney U test was utilized as statistical tests for the data 
presented in A, B, and C. *P < 0.05, **P < 0.01, ***P < 0.001.  
 
Fig. 3. A: High concentration of progesterone (P4) and moderate levels of androstenedione (A-
dione), testosterone (T), and dihydrotestosterone (DHT) are detected in the adrenal glands of intact 
and orchectomized mice. B: Adrenal to serum ratios for P4, A-dione, T, and DHT, indicating their 
local production. A and B: Intact n=14 and ORX n=11. All measurements were performed at the 
end of the study, 63 days after ORX and 110 or with intact 84 days after cell inoculations. Data are 
expressed as median and range. Mann-Whitney U test was utilized for statistical analysis. ***P < 
0.001. 
 
Fig. 4. A: Concentrations of serum progesterone (P4), androstenedione (A-dione), testosterone (T), 
and dihydrotestosterone (DHT) in intact (n=15), orhectomized (ORX n=14), and ORX+ADX 
(n=13) mice. B: ORX alone has no effect on intratumoral P4, T, or DHT, whereas adrenalectomy 
(ADX) combined with ORX results in a marked decrease in intratumoral steroids. C: Tumor to 
serum ratios for P4, A-dione, T, and DHT indicate an intratumoral production of active androgens in 
ORX and ORX+ADX mice. B and C: Intact n=10, ORX n=14, and ORX+ADX n=13. All 
measurements were performed at the end of the study, about 62 days after ORX and ORX+ADX or 
with intact 84 days after cell inoculations. Data are expressed as median and range. Kruskal-Wallis 
with Dunn’s post hoc test was utilized for statistical analyses. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Fig. 5. A: Expression of full-length AR (AR-FL), and AR-V1 and AR-V7 splice variant mRNA is 
increased in VCaP tumors by orchectomy (ORX), and the expression of the mRNAs show trend for 
further increase by adrenalectomy (ORX+ADX). B: Western blot analysis of AR protein in the 
VCaP tumors indicate that the induction of mRNA expression by ADX in ORX mice is not 
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translated to a higher AR protein expression, whereas ORX markedly increases both mRNA and 
protein levels. The intensities of AR signals are normalized to that of the beta-actin, and the values 
relative for that obtained for the tumors in intact mice are shown for the tumors in ORX and 
ORX+ADX mice. C: Expression of mRNAs for steroid synthetic enzymes measured by RT-qPCR, 
showing only modest differences between intact, ORX, and ADX+ORX groups. D: Relative 
mRNA expression of androgen-regulated genes SYTL2, NOV, FKBP5, ST6Ga1NAc1, PMEPA1, 
KLK2, KLK3, and KLK4 in intact, ORX, and ORX+ADX tumors measured by RT-qPCR. All 
measurements were performed at the end of the study, about 63 days after ORX and ORX+ADX or 
with intact 84 days after cell inoculations. RT-qPCR results are normalized to L19 expression. Data 
are expressed as mean±SEM (A, C, and D). The Kruskal-Wallis with Dunn’s post hoc test was 
utilized for statistical testing of the data in A, C, and D. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Table 1: Real-Time Quantitative Reverse Transcription-PCR Primer Sequences 
 
Human gene Forward  Reverse 
AKR1C2  5’- CCTAAAAGTAAAGCTCTAGAGGCCGT4 -3’ 5’- GAAAATGAATAAGATAGAGGTCAACATAG -3’ 
AKR1C3 5’- GCCAGGTGAGGAACTTTCAC -3’ 5’- CAATTTACTCCGGTTGAAATACG -3’ 
AR-FL 5’- CTTACACGTGGACGACCAGA -3’ 5’- GCTGTACATCCGGGACTTGT -3’ 
AR-V1 5’- CCATCTTGTCGTCTTCGGAAATGTTATGAAGC -3’ 5’- CTGTTGTGGATGAGCAGCTGAGAGTCT -3’ 
AR-V7 5’- CCATCTTGTCGTCTTCGGAAATGTTATGAAGC -3’ 5’- TTTGAATGAGGCAAGTCAGCCTTTCT -3’ 
FKBP5 5’- AAAAGGCCACCTAGCTTTTTGC -3’ 5’- CCCCCTGGTGAACCATAATACA -3’ 
HSD17B3 5’- CTGAAGCTCAACACCAAGGTCA -3’ 5’- CTGCTCCTCTGGTCCTCTTCAG -3’  
KLK2  5’- CTGCCCATTGCCTAAAGAAGAA -3’ 5’- GGCTTTGATGCTTCAGAAGGCT -3’ 
KLK3 5’- CCAAGTTCATGCTGTGTGCT -3’ 5’- GGTGTCCTTGATCCACTTCC -3’ 
KLK4 5’- GGCACTGGTCATGGAAAACGA -3’ 5’- TCAAGACTGTGCAGGCCCAGC -3’ 
NOV 5’- ACCGTCAATGTGAGATGCTG -3’ 5’- TCTTGAACTGCAGGTGGATG -3’ 
PMEPA1 5’- TGCCGTTCCATCCTGGTT -3’ 5’- AGACAGTGACAAGGCTAGAGAAAGC -3’ 
L19 5’- AGGCACATGGGCATAGGTAA -3’ 5’- CCATGAGAATCCGCTTGTTT -3’ 
SRD5A1  5’- CCTGTTGAATGCTTCATGACTTG -3’ 5’- TAAGGCAAAGCAATGCCAGATG -3’ 
SRD5A2 5’- CTCTCTAAGGAAGGGGCCGAAC -3’  5’- GACAATGCATTCCGCAAACATA -3’  
ST6GalNAc1 5’- AGGCACAGACCCCAGGAAG -3’ 5’- TGAAGCCATAAGCACTCACC -3’ 
SYTL2 5’- TCTGCCTTGAGAAAACAAACAG T -3’ 5’- GCCAGTGGGTGGCACTAAAA -3’ 
Mouse gene Forward  Reverse 
Ar 5’- GTCTCCGGAAATGTTATGAA -3’ 5’- AAGCTGCCTCTCTCCAAG -3’ 
Akr1c6 5’- CAGACAGTGCGTCTAAGTGATG -3’ 5’- CGGATGGCTAGTCCTACTTCCT-3’  
Akr1c18 5’- TGGCACTGTGAAAAGGGAAGAT -3’ 5’- TTAGGCAAAAGCTCATTCCCTGG -3’ 
Akr1d1 5’- TTGCGTTTCAACATCCAGCG -3’ 5’- AGCAACTCCACATAGCGGAC -3’  
Cyp11a1 5’- AGATCCCTTCCCCTGGCGACAATG -3’ 5’- CGCATGAGAAGAGTATCGACGCATC -3’ 
Cyp17a1 5’- CAAGCCAAGATGAATGCAGA -3’ 5’- AGGATTGTGCACCAGGAAAG -3’ 
Hsd3b1 5’- CAGGAGCAGGAGGGTTTGTG -3’ 5’- GTGGCCATTCAGGACGAT -3’ 
Hsd3b2 5’- CAGTTGTTGGTGCAAGAGGA -3’ 5’- CCTGGGAATGACACCTGTGA -3’  
Hsd17b3 5’- CACGGGGATAAAGACCAGGT -3’ 5’- GATCGCAGGAAAGAGCTTGG -3’ 
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Hsd17b6 5’- TTTGGAGGATTCTACAGTTGCTC -3’  5’- TCACCCCGAAATCTTGAACCT -3’ 
L19 5’- GGACAGAGTCTTGATGATCTC -3’ 5’- CTGAAGGTCAAAGGGAATGTG -3’ 
Lhcgr 5’- GCCCTGAGCCCTGCGACTGC -3’ 5’- AAAGCGTTCCCTGGTATGGTGGTT -3’ 
Mc2r 5’- TCTGACATCATGTTGGGCAGTCT -3’ 5’- TGGTGATGTAACGGTCAGCT -3’ 
Srd5a1 5’- TGAGCCAGTTTGCGGTGTAT -3’ 5’- CTCCACGAGCTCCCCAAAAT -3’ 
Srd5a2 5’- CACAGACATGCGGTTTAGCG -3’ 5’- AACAAGCCACCTTGTGGGAT -3’ 
Srd5a3 5’- CTGGCTTAGTGCTCTGCTCA -3’ 5’- CACAACGTGAATGGCTGCAT -3’ 
Ugt1a1 5’- GCAGAGTGGTTTATTCCCCCT -3’ 5’- AGGCGTTGACATAGGCTTCAA -3’ 
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